Tolterodine Tartrate
Therapeutic Class: Urological (BPH/ Urinary retention/ Urinary incontinence)
Indications:
Tolterodine Tartrate is indicated for the treatment of overactive bladder with symptoms of urinary urgency, frequency, and/or urge incontinence.
Presentation:
Tolterodine Tartrate 2: Each tablet contains Tolterodine Tartrate INN 2 mg
Description:
Tolterodine is a competitive, specific muscarinic receptor antagonist, which exhibits selectivity for the urinary bladder over salivary glands. One of the tolterodine metabolites (5-hydroxymethyl derivative) exhibits a pharmacological profile similar to that of the parent compound. In extensive metabolisers this metabolite contributes significantly to the therapeutic effect.
Indications:
Tolterodine Tartrate is indicated for the treatment of overactive bladder with symptoms of urinary urgency, frequency, and/or urge incontinence.
Dosage & Administration:
The recommended dose is 2 mg b.i.d. In the case of troublesome side effects, the dose may be reduced from 2 mg to 1 mg b.i.d.
The recommended dose is 1 mg b.i.d. for patients with impaired renal function, impaired liver function, or receiving concomitant ketoconazole or other potent CYP3A4 inhibitors.
Side Effects:
Tolterodine may cause mild-to-moderate antimuscarinic effects, like dryness of the mouth, dyspepsia, and reduced lacrimation.
Precautions:
Tolterodine should be used with caution in the patients at risk for urinary retention & decreased gastrointestinal motility, with impaired renal & hepatic function, and with myasthenia gravis.
Use in Pregnancy & Lactation:
There are no studies on pregnant women. Therefore, tolterodine should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. Use of tolterodine during lactation should be avoided since no data on excretion into breast milk in humans are available.
Interaction:
Ketoconazole, a potent inhibitor of CYP3A4, significantly increased plasma concentrations of tolterodine when co-administered to poor metabolisers. For patients receiving ketoconazole or other potent CYP3A4 inhibitors, the recommended total daily dose is 2 mg.
Overdose:
Treatment of overdosage with Tolterodine should consist of activated charcoal. Activated charcoal is usually most effective when administered within 1-hour of ingestion. Ipecac-induced emesis is not recommended, and dialysis is not likely to be of benefit as tolterodine is highly protein-bound.
Storage:
Store in a cool and dry place. Protect from light. Keep out of the reach of children.
Tolterodine Tartrate is indicated for the treatment of overactive bladder with symptoms of urinary urgency, frequency, and/or urge incontinence.
Presentation:
Tolterodine Tartrate 2: Each tablet contains Tolterodine Tartrate INN 2 mg
Description:
Tolterodine is a competitive, specific muscarinic receptor antagonist, which exhibits selectivity for the urinary bladder over salivary glands. One of the tolterodine metabolites (5-hydroxymethyl derivative) exhibits a pharmacological profile similar to that of the parent compound. In extensive metabolisers this metabolite contributes significantly to the therapeutic effect.
Indications:
Tolterodine Tartrate is indicated for the treatment of overactive bladder with symptoms of urinary urgency, frequency, and/or urge incontinence.
Dosage & Administration:
The recommended dose is 2 mg b.i.d. In the case of troublesome side effects, the dose may be reduced from 2 mg to 1 mg b.i.d.
The recommended dose is 1 mg b.i.d. for patients with impaired renal function, impaired liver function, or receiving concomitant ketoconazole or other potent CYP3A4 inhibitors.
Side Effects:
Tolterodine may cause mild-to-moderate antimuscarinic effects, like dryness of the mouth, dyspepsia, and reduced lacrimation.
Precautions:
Tolterodine should be used with caution in the patients at risk for urinary retention & decreased gastrointestinal motility, with impaired renal & hepatic function, and with myasthenia gravis.
Use in Pregnancy & Lactation:
There are no studies on pregnant women. Therefore, tolterodine should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. Use of tolterodine during lactation should be avoided since no data on excretion into breast milk in humans are available.
Interaction:
Ketoconazole, a potent inhibitor of CYP3A4, significantly increased plasma concentrations of tolterodine when co-administered to poor metabolisers. For patients receiving ketoconazole or other potent CYP3A4 inhibitors, the recommended total daily dose is 2 mg.
Overdose:
Treatment of overdosage with Tolterodine should consist of activated charcoal. Activated charcoal is usually most effective when administered within 1-hour of ingestion. Ipecac-induced emesis is not recommended, and dialysis is not likely to be of benefit as tolterodine is highly protein-bound.
Storage:
Store in a cool and dry place. Protect from light. Keep out of the reach of children.